Xeris Biopharma Holdings Aktie News

Xeris Biopharma Holdings, Inc. ( XERS ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Allison Wey - Senior Vice President of Investor Relations & Corporate Communications John Shannon - CEO & Director Steven Pieper - Chief Financial Officer Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Chase Knickerbocker - Craig-Hallum Capital Group LLC, ...

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the third quarter ended September 30, 2025. “We delivered another record-breaking quarter, driven by increased patient demand...

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its third quarter 2025 financial results before the open of the U.S. financial markets on Thursday, November 6, 2025....

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on October 1, 2025, the Compensation Committee of Xeris' Board of Directors granted restricted stock units for an aggregate of 382,975 shares ...

Xeris Biopharma delivered record Q2 revenue, driven by Recorlev's rapid adoption, and is on track to achieve breakeven in Q3. Recorlev is the primary growth engine, while Gvoke provides steady diversification; Keveyis' contribution is expected to continue declining. XP-8121, a once-weekly levothyroxine, offers significant long-term upside but introduces future funding risks for Phase 3 trials.

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced the U.S Patent and Trademark Office has issued patent number 12,377,096 to the Company for Recorlev® (levoketoconazole) and that this patent is now...

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Allison Wey - Senior Vice President of Investor Relations & Corporate Communications John P. Shannon - CEO & Director Steven M.

Xeris (XERS) Q2 Revenue Jumps 49%